30-Mar-2026
Globe Newswire (Thu, 12-Mar 4:01 PM ET)
Globe Newswire (Thu, 5-Mar 4:01 PM ET)
Corvus Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Globe Newswire (Mon, 23-Feb 4:01 PM ET)
Market Chameleon (Mon, 26-Jan 3:17 AM ET)
Globe Newswire (Fri, 23-Jan 5:00 PM ET)
Corvus Pharmaceuticals Raises $175 Million in Upsized Offering to Power Key Immunotherapy Trials
Market Chameleon (Thu, 22-Jan 5:34 AM ET)
Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
Globe Newswire (Wed, 21-Jan 10:53 PM ET)
Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Globe Newswire (Tue, 20-Jan 4:01 PM ET)
Market Chameleon (Tue, 20-Jan 5:29 AM ET)
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.
Corvus Pharmaceuticals trades on the NASDAQ stock market under the symbol CRVS.
As of March 30, 2026, CRVS stock price declined to $13.40 with 1,221,877 million shares trading.
CRVS has a beta of 0.97, meaning it tends to be less sensitive to market movements. CRVS has a correlation of 0.01 to the broad based SPY ETF.
CRVS has a market cap of $1.13 billion. This is considered a Small Cap stock.
Last quarter Corvus Pharmaceuticals reported $0 in Revenue and -$.15 earnings per share. This fell short of revenue expectation by $-620,000 and missed earnings estimates by -$.01.
In the last 3 years, CRVS traded as high as $26.95 and as low as $.72.
The top ETF exchange traded funds that CRVS belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.
CRVS has outperformed the market in the last year with a return of +296.4%, while the SPY ETF gained +15.1%. In the last 3 month period, CRVS beat the market returning +78.9%, while SPY returned -7.7%. However, in the most recent 2 weeks CRVS has underperformed the stock market by returning -14.8%, while SPY returned -5.3%.
CRVS support price is $13.37 and resistance is $14.65 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRVS shares will trade within this expected range on the day.